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Abstract: In this 2 × 2 factorial, outcome-assessor blinded, feasibility randomised trial we explored 
the effect of a non-pharmaceutical multi-component intervention on periodontal health and metabolic 
and infammatory profles among pregnant women with periodontitis receiving prenatal care in a 
Brazilian public health centre. 69 pregnant women (gestational age ≤20 weeks, T0) were randomly 
allocated into four groups: (1) fortifed sachet (vitamin D and calcium) and powdered milk plus 
periodontal therapy during pregnancy (early PT) (n = 17); (2) placebo sachet and powdered milk 
plus early PT (n = 15); (3) fortifed sachet and powdered milk plus late PT (after delivery) (n = 19); 
(4) placebo sachet and powdered milk plus late PT (n = 18). Third trimester (T1) and 6–8 weeks 
postpartum (T2) exploratory outcomes included periodontal health (% sites with bleeding on probing 
(BOP)), glucose, insulin, C-Reactive Protein, serum calcium and vitamin D. The mean BOP was 
signifcantly reduced in the early PT groups, while BOP worsened in the late PT groups. No 
signifcant effect of fortifcation on BOP was observed. Changes in glucose levels and variation 
on birthweight did not differ among groups This feasibility trial provides preliminary evidence 
for estimating the minimum clinically important differences for selected maternal outcomes. A 
large-scale trial to evaluate the interventions’ clinical benefts and cost-effectiveness is warranted. 
Keywords: exploratory effcacy; feasibility trial; pregnant women; calcium; vitamin D; periodontitis 
Copyright: © 2021 by the authors. 
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Periodontitis is a chronic infammatory disease affecting the periodontium and tooth-
supporting structures such as alveolar bone and its progression can lead to tooth loss [1]. 
Periodontitis is a highly prevalent condition among adults and affects 10–43.7% of the 
general adult population worldwide [2]. While periodontitis is common in women of 
reproductive age, gingival infammation tends to worsen during pregnancy due to hor-
monal changes [3–5]. This infammatory burden can affect maternal health beyond the 
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oral cavity leading to a low-grade systemic infammatory status and metabolic distur-
bances, infuencing the course of gestation [6]. There is evidence supporting the association 
between periodontal infammation and diabetes [7]. Treating or reducing infammatory 
periodontal diseases results in improvements in glycaemic control which in turn can reduce 
microvascular complications of diabetes [7]. 
Maternal chronic periodontitis thus increases the risk of poor pregnancy and birth 
outcomes including preterm delivery, low birth weight, gestational diabetes and pre-
eclampsia [6,8,9]. Fortunately, periodontitis is a treatable and preventable disease and 
screening for this condition during pregnancy should not be overlooked by health care 
professionals. However, previous systematic reviews on the effect of periodontal treat-
ment during pregnancy on maternal infammatory and metabolic profle and gestational 
outcomes yielded inconsistent results [10–12]. 
A systematic review with meta-analysis including four randomised clinical trials 
(RCT) of non-surgical periodontal treatment during pregnancy failed to demonstrate 
consistent improvement in gestational outcomes [11]. For instance, the review found 
an overall reduction of 46% in the risk of preterm delivery, but no signifcant reduction 
in the risk for low birth weight [11]. Although periodontal therapy improved maternal 
periodontal clinical parameters, no signifcant reduction in the levels of infammatory 
markers in cord blood samples was detected [11]. Another systematic review including 
twenty RCTs investigated the effect of any type of periodontal treatment during pregnancy 
on perinatal mortality and found a signifcantly decreased risk of perinatal mortality 
among those in the treatment group [10]. The review also found a reduction in preterm 
birth and an increase in birthweight. However, periodontal treatment did not reduce the 
risk of preeclampsia, gestational diabetes, cesarean section, small for gestational age, or 
congenital malformations [10]. Finally, a recent systematic review, including 19 RCTs on 
non-surgical periodontal treatment during pregnancy [12], concluded that this type of 
therapy is safe during pregnancy, and even though it does not entirely prevent adverse 
pregnancy outcomes, it can be safely recommended as a part of routine prenatal care. 
Considering the available evidence, it seems desirable to fnd co-adjuvant therapies that 
could enhance the benefts of non-surgical periodontal treatment during pregnancy. 
Periodontitis is a multifactorial condition and there is evidence that diet and nutritional 
status play an important role in the disease progression [13]. Observational studies have 
shown that vitamin D and calcium defciency result in increased infammation and bone 
loss, suggesting that low vitamin D and calcium levels are risk factors for periodontitis [14] 
and that adequate intakes of vitamin D and calcium, particularly from milk, are associated 
with a lower risk of dental plaque [15], periodontitis [14,16,17] and tooth loss [18] in adults. 
A cross-sectional study in an adult population evaluated the serum levels of vitamin D and 
calcium in periodontally healthy, chronic gingivitis and chronic periodontitis patients with 
and without type two diabetes mellitus [19]. The study consistently found that vitamin 
D and calcium levels were inversely correlated with random blood sugar and glycated 
haemoglobin and also pocket depth and clinical attachment loss, thus contributing towards 
an increase in periodontal disease severity [19]. 
A recent meta-analysis found that calcium and vitamin D supplementation signif-
icantly improved clinical responses to non-surgical periodontal treatment compared to 
placebo [20]. However, no previous studies have been conducted among pregnant women. 
Furthermore, dietary supplementation with vitamin D and calcium has other health 
benefts beyond those for oral health and a recent RCT found that calcium-vitamin D 
co-supplementation for nine weeks during pregnancy among women at high-risk for 
pre-eclampsia resulted in lower fast plasma glucose and serum triglycerides levels in the 
intervention group compared to control [21]. It has also been observed that calcium-vitamin 
D co-supplementation signifcantly decreased C-reactive protein and blood pressure [22]. 
Yet, both the intakes of dairy and calcium [23] and access to periodontal therapy are 
disproportionally low in South America and other low- and middle-income countries 
compared to high-income countries. 
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We, therefore, undertook a small-scale trial on non-surgical periodontal treatment 
combined with milk fortifcation with vitamin D and calcium during pregnancy in a de-
prived area of Rio de Janeiro to investigate its feasibility [24,25]. Exploratory studies, also 
known as pilot and feasibility studies, are crucial in assessing the feasibility and value of 
progressing to an effectiveness study, and by this means reducing costs and minimising po-
tential harms of interventions [26]. Additionally, exploratory studies provide a preliminary 
assessment of effect sizes which can inform an accurate estimation of the sample size for the 
full-scale trial and other trial design parameters [26]. We found that our multi-component 
intervention was well tolerated and accepted by pregnant women and that the trial design 
was feasible with minor modifcations [24]. In this paper, the potential impact of this 
exploratory feasibility trial on maternal periodontal clinical outcomes, infammatory and 
metabolic markers are reported. 
2. Methods 
2.1. Study Design 
The detailed study protocol for this 2× 2 factorial randomised controlled feasibility trial 
with a parallel process evaluation i.e., the groups were not cross-over, has been described 
previously [27]. The reporting of this study is in accordance with the extension of the Consoli-
dated Standards of Reporting Trials (CONSORT) statement for randomised pilot and feasibility 
trials [28]. Participants were allocated to one of four intervention groups using a permutated 
block randomisation matrix, stratified by smoking status (Figure 1) provided and concealed 
by Sealed Envelope Ltd. (London, UK). The intervention groups were as follows: 1 fortified 
sachet with vitamin D and calcium and powdered milk plus periodontal treatment (PT) during 
pregnancy, 2 placebo sachet and powdered milk plus PT during pregnancy, 3 fortified sachet 
and powdered milk plus PT after delivery and 4 placebo sachet and powdered milk plus PT 
after delivery. The study follows the CONSORT reporting standards. Nutrients 2021, 13, x FOR PEER REVIEW 4 of 16 
 
 
Figure 1. Flowchart of enrolment, allocation, and follow-up of the pregnant women from a low 
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2.2. Study Population and Eligibility Criteria 
This study was conducted among adult (>18 years) pregnant women attending pre-
natal care at a Public Health Centre in Duque de Caxias in Rio de Janeiro, Brazil. During 
prenatal booking at the health centre, pregnant women were referred by nurses to the 
study team, who applied a preliminary eligibility checklist.  To be eligible women had to 
be up to 20 weeks gestation at their first prenatal visit at the Health Centre, without a 
diagnosis of HIV/AIDS, syphilis, psychosis, diabetes prior to pregnancy, thyroid disease, 
any condition causing vitamin D hypersensitivity (e.g. lymphomatous disorders) or a his-
tory of renal stones or family history of renal stone and hyperparathyroidism. Participants 
reporting lactose intolerance and/or milk allergy, intake of antibiotics or any immune-
suppressants or medication known to affect vitamin D/calcium metabolism, consumption 
of ≥4 servings/day of dairy products, or taking vitamin D supplements at > 400 IU/day 
and using dental braces were excluded.  
Those initially eligible were invited to take part in a dental screening, conducted by 
one trained dentist. Women with ≥ 1 tooth with at least one site with ≥ 4mm of clinical 
attachment loss (CAL) and presence of bleeding on probing (BOP) on the same site were 
classified as having periodontitis and invited to take part in the study. Women with ex-
tensive dental cavities and decay were then excluded. 
2.3. Intervention 
The intervention included a serving of commercially available semi-skimmed pow-
dered milk (20g) and a sachet (2g) with vitamin D3 (500 IU) and dairy calcium (CAPOLAC 
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2.2. Study Population and Eligibility Criteria 
This study was conducted among adult (>18 years) pregnant women attending pre-
natal care at a Public Health Centre in Duque de Caxias in Rio de Janeiro, Brazil. During 
prenatal booking at the health centre, pregnant women were referred by nurses to the study 
team, who applied a preliminary eligibility checklist. To be eligible women had to be up to 
20 weeks gestation at their frst prenatal visit at the Health Centre, without a diagnosis of 
HIV/AIDS, syphilis, psychosis, diabetes prior to pregnancy, thyroid disease, any condition 
causing vitamin D hypersensitivity (e.g., lymphomatous disorders) or a history of renal 
stones or family history of renal stone and hyperparathyroidism. Participants reporting 
lactose intolerance and/or milk allergy, intake of antibiotics or any immune-suppressants 
or medication known to affect vitamin D/calcium metabolism, consumption of ≥4 serv-
ings/day of dairy products, or taking vitamin D supplements at >400 IU/day and using 
dental braces were excluded. 
Those initially eligible were invited to take part in a dental screening, conducted by 
one trained dentist. Women with ≥1 tooth with at least one site with ≥4 mm of clinical 
attachment loss (CAL) and presence of bleeding on probing (BOP) on the same site were 
classifed as having periodontitis and invited to take part in the study. Women with 
extensive dental cavities and decay were then excluded. 
2.3. Intervention 
The intervention included a serving of commercially available semi-skimmed pow-
dered milk (20 g) and a sachet (2 g) with vitamin D3 (500 IU) and dairy calcium (CAPOLAC 
500 mg) to be consumed twice a day during breakfast and afternoon snack or supper. Par-
ticipants were advised to avoid milk consumption during main meals (lunch and dinner) 
to prevent concomitant intake of the prenatal iron supplements provided as part of the 
routine prenatal care in Brazil. Women in the control group were given the same amount 
of semi-skimmed milk powder with a non-fortifed sachet (placebo) with similar colour, 
favour, smell and texture. Participants were asked to reconstitute the 20 g of powdered 
milk and the content of the sachet into 200 mL of potable water for each serving. Sachets 
and milk were provided monthly to participants. Women were encouraged to drink the 
milk or add the content in preparations including porridges, smoothies, or kneaded fruits. 
Right after randomisation, participants allocated to the early PT group underwent 
a conventional non-surgical PT throughout pregnancy up to childbirth, consisting of 
prophylactic dental polishing to remove the bacterial flm, scaling and root planning, as 
necessary. The number of therapy sessions varied according to disease severity with a 
maximum of fve sessions per participant. The treatment was performed by a trained 
dentist who was not involved in dental screening. Participants allocated to the late PT 
group started the treatment after childbirth as part of the routine dental care in the health 
centre. In each session, all women were given personalised oral hygiene instructions. 
At the beginning of the study, all participants were given a brochure with information 
about the benefts of dairy food intake during pregnancy, a healthy diet and oral health 
hygiene instructions. Participants also received fuoride toothpaste, a toothbrush and dental 
foss. All women regardless of group allocation were advised not to change their routine 
physical activity neither consume any other supplements apart from the ones provided 
by the health centre (usually 400 µg/d folic acid and 60 mg/d ferrous sulphate). All 
women with young children (older than six months) were given a surplus of commercially 
available whole milk powder to ensure mothers did not share their milk provision with 
their families. 
2.4. Data Collection 
Baseline data (T0) were collected before randomisation and after checking for par-
ticipant eligibility to the trial. Baseline data were collected up to the second trimester of 
pregnancy. The study included two additional follow-ups: T1 during the third trimester of 
pregnancy (30–38 gestational weeks) and T2 at 6–8 weeks postpartum. 
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At the three time-points (T0, T1 and T2), participants answered structured question-
naires about their general health, social support and lifestyle. Information on socioeconomic 
demographics was provided at baseline only. 
Maternal blood samples were collected in the morning after 12-h overnight fast in 
all three-time points for analysis of biochemical markers. Blood samples were stored in a 
freezer with a temperature of −80 ◦C until analysis at the Institute of Nutrition Josué de 
Castro at the Federal University of Rio de Janeiro. Fasting serum glucose (mg/dL) levels 
were estimated by an enzymatic colorimetric method and fasting serum insulin (µU/mL) 
by chemiluminescence. Serum calcium concentrations (mg/dL) were analysed using an 
automated colorimetric technique, 25-hydroxyvitamin D (25(OH)D) serum concentrations 
(ng/mL) levels were determined by the method of high-pressure liquid chromatography 
(HPLC), serum ultra-sensitive C-Reactive Protein (CRP) (mg/L) levels were measured by 
the immunoturbidimetric method. Birthweight (g) information was extracted from the 
medical records. 
2.5. Oral Health Examination 
After the initial oral health screening during the recruitment phase, women with 
confrmed periodontitis who agreed to take part in the study underwent a full-mouth 
periodontal examination at baseline (T0) and postpartum (T2) regardless of group allocation. 
Periodontal examination was performed at six sites per tooth including mesiobuccal, mid-
buccal, distobuccal, mesiolingual, mid-lingual and distolingual sites, using colour-coded 
North Carolina periodontal probes and a dental mirror. No x-ray was taken. Additionally, 
bi-monthly maintenance periodontal examinations were performed in those who had 
fnished the PT during pregnancy. A tailored form was developed to register the data on 
gingival bleeding on probing (BOP), probing depth (PD), clinical attachment loss (CAL) 
and dental mobility. Calibrated and trained dentists performed oral examinations and PT. 
The dentists calibrated their probing force using a scale prior to all examinations to ensure 
that adequate pressure of approximately 20 g was applied [29]. The dentist who performed 
the periodontal examination was blinded regarding group allocation. 
2.6. Analysis 
The distribution of the outcomes was evaluated via visual inspections of charts and 
statistical tests for normality. The sample baseline characteristics were described by means 
and standard deviations (±SD) or absolute (n) and relative frequencies (%) in each time-
point of each intervention group. One-way ANOVA and Pearson’s chi-squared tests were 
applied for comparison between intervention groups. 
The results were presented using both intention-to-treat (ITT) and per-protocol analysis. 
The ITT refers to a comparison of the treatment groups that include all women as originally 
allocated after the randomisation. In the case of missing observations, the ‘last value carried 
forward’ approach was used [30]. The per-protocol analysis refers to the comparison 
of treatment groups that include only those participants who completed the treatment 
originally allocated [30]. 
The treatment variation over time (delta) across groups was mainly calculated as 
the difference between the mean values at the end of the study (T2) and baseline (T0) 
however mean differences in each time points (T1–T0 and T2–T1) were also estimated 
to aid interpretation of results as some parameters might have a different distribution 
during pregnancy and postpartum. Caution should be exercised when interpreting the 
delta values as the aim of this feasibility trial was not to assess effectiveness and therefore 
is underpowered to do this [28]. 
BOP is the main clinical outcome for this study. In addition to examining how BOP 
varied over time in different treatment groups, we are also interested in exploring potential 
interactions of effect modifers on BOP beyond group allocation. For example, although 
serum calcium levels and insulin concentrations were initially considered in the analysis as 
metabolic outcomes, we also explored the independent impact of these variables on BOP. 
Nutrients 2021, 13, 783 6 of 15 
A factorial ANOVA type III that is robust for unbalanced factorial design and can identify 
any potential interactions between intervention groups was performed. However, it is 
important to consider that the study was not designed nor powered to identify statistically 
signifcant interactions and further ANOVA type II analyses were also used to explore the 
interventions interactions on all outcomes. For all statistically signifcant outcomes in the 
previous analyses, an analysis of covariance (ANCOVA) considering the remaining primary 
outcomes as infuence factors was performed and results were graphically displayed. All 
tests considered an alpha of 0.05 with no corrections for multiplicity of tests. All analyses 
were performed using R statistical software version 4.0.2 (R Core Team, Vienna, Austria). 
3. Results 
The mean (±SD) age and gestational age of 69 women who participated in the study at 
the baseline was 27.9 (±5.7) years and 16.2 (±2.4) weeks, respectively. On average, women 
had 10.5 (±2.2) years of schooling and a pre-pregnancy BMI of 27.3 (±7.0) kg/m2. The 
majority of the women reported living with a partner (86.9%), self-ascribed as mixed or 
black skin colour (88.4%), did not smoke (88.4%) nor consumed alcohol during pregnancy 
(82.6%). The mean parity was 1.2 (1.2) and 65.2% had another child prior to the study 
enrolment. Regarding their oral health, the mean pocket depth was 4.2 (±0.2) mm. The 
clinical attachment loss was 4.3 (±0.2) mm and approximately one-quarter of the sites had 
bleeding on probing in all intervention groups at baseline. After randomisation, all baseline 
characteristics were equally distributed across intervention groups and no statistically 
signifcant differences were found between them (Table 1). Therefore, these potential 
confounders are unlikely to infuence the impact of the intervention among groups. 
Table 1. Baseline a characteristics by intervention groups of pregnant women with periodontitis from a low socioeconomic 
area in Rio de Janeiro, Brazil. 
Early PT Late PT 
Variables Fortifcation Placebo Fortifcation Placebo p-Value b 
Age (years) (mean, SD) 27.5 (6.4) 26.5 (6.3) 28.7 (6.0) 28.8 (4.3) 0.63 
Schooling (years) (mean, SD) 10.2 (2.3) 10.5 (2.3) 10.7 (1.8) 10.7 (2.7) 0.93 
Per-capita income (USD) c (mean, SD) 105.9 (60.5) 181.9 (146.6) 162.1 (111.5) 159.7 (106.6) 0.23 
Marital status (n, %) 









2 (22.2) 0.43 
Self-reported skin colour (n, %) 
White 








15 (24.5) 0.36 
e 
Gestational age (weeks) (mean, SD) 16 (2.5) 15 (2.5) 17 (2.1) 16 (2.6) 0.60 
Pre-pregnancy BMI (kg/m2) (mean, 
SD) 
26.3 (6.5) 27.1 (8.0) 27.7 (4.5) 28.0 (9.2) 0.23 
Parity (number of parturitions) (n, %) 
No previous delivery 








13 (28.8) 0.86 










2 (25.0) 0.85 
e 










3 (25.0) 0.90 
e 
Pocket depth (mm) (mean, SD) 4.3 (0.19) 4.21 (0.21) 4.22 (0.19) 4.28 (0.24) 0.51 
Clinical attachment loss (mm) (mean, 
SD) 4.3 (0.20) 4.24 (0.23) 4.27 (0.19) 4.3 (0.27) 0.89 
Sites with bleeding on probing (BOP) 
(mean, SD) 0.21 (0.15) 0.20 (0.14) 0.15 (0.11) 0.23 (0.16) 0.33 
a Baseline was between gestational weeks 11 and 21. b ANOVA test applied for continuous variables and Chi2 test for categorical variables. 
c Value originally measured in Brazilian Reais (BRL) but converted to USA dollars (USD). Exchange rate in February 2019, BRL 3.75 = USD 1. 
d Other = Not living with a partner or do not have a partner. e Fisher test applied. BMI, Body Mass Index. 
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Table 2 (per-protocol analysis) shows that the variation (delta: T2–T0) of BOP over time 
signifcantly differed between early and late PT groups. The mean BOP was signifcantly 
reduced in the early PT groups (Fortifcation: −0.1 ± 0.15; Placebo: −0.11 ± 0.15), while 
BOP increased (or worsened) in the late PT groups (Fortifcation: 0.04 ± 0.19; Placebo: 
0.07 ± 0.15). There was a trend towards a slight reduction in both PD and CAL in the early 
PT compared to late PT, but results were not statistically signifcant (p-value > 0.05). 
Table 2. Main outcomes per-protocol according to intervention groups in pregnant and postpartum women participating in 
the IMPROVE trial. 
Early PT Late PT 
Fortifcation Placebo Fortifcation Placebo p 








T0 0.23 (0.16) 0.21 (0.18) 0.15 (0.11) 0.23 (0.16) 
T2 13 0.13 (0.12) 9 0.09 (0.07) 17 0.19 (0.20) 16 0.29 (0.18) 
ΔT −0.10 (0.15) 
−0.11 




T0 4.34 (0.20) 4.25 (0.24) 4.25 (0.19) 4.27 (0.25) 
T2 13 4.28 (0.19) 9 4.22 (0.26) 17 4.20 (0.13) 16 4.29 (0.17) 




(0.21) 0.02 (0.22) 0.66 (0.31) 
CAL (mm) 
T0 4.34 (0.21) 4.32 (0.27) 4.29 (0.18) 4.29 (0.29) 
T2 13 4.32 (0.19) 9 4.29 (0.34) 17 4.37 (0.43) 16 4.29 (0.17) 
ΔT −0.02 (0.23) 
−0.03 
(0.30) 0.08 (0.48) 0.00 (0.27) 0.18 (0.36) 
Calcium (mg/dL) 




9.1 (0.7) 9 
8.8 (0.6) 
8.7 (0.6) 17 
8.9 (0.4) 
9.2 (0.6) 15 
9.0 (0.8) 
9.0 (0.7) 
ΔT 0.1 (1.0) −0.6 (0.7) −0.1 (0.6) 0.1 (0.6) 0.53 (0.75) 
Vitamin D (ng/mL) 




23.4 (10.5) 9 
27.3 (7.8) 
28.8 (11.5) 17 
31.2 (8.8) 
27.2 (7.1) 16 
32.6 (10.0) 
28.1 (9.5) 
ΔT −1.8 (9.5) −1.3 (12.1) −3.3 (6.7) −3.5 (5.4) 0.43 (0.97) 
CRP (mg/L) 




6.4 (4.9) 9 
6.3 (3.5) 
7.6 (7.5) 17 
12.7 (8.2) 
7.2 (7.4) 16 
10.8 (8.7) 
4.6 (3.5) 
ΔT −5.9 (7.1) −1.3 (9.5) −4.0 (7.8) −4.2 (4.8) 0.90 (0.41) 
Glucose (mg/dL) 




80.2 (14.6) 9 
68.0 (8.4) 
75.9 (6.8) 17 
73.7 (13.2) 
78.5 (11.5) 16 
78.8 (14.5) 
81.3 (11.8) 
ΔT 8.9 (16.9) 2.5 (8.7) 4.6 (12.9) 8.6 (11.8) 0.92 (0.99) 
Insulin (µU/mL) 




7.6 (5.2) 9 
9.0 (3.5) 
5.7 (2.8) 17 
11.4 (4.4) 
5.0 (2.5) 16 
10.3 (3.9) 
4.5 (1.9) 
ΔT −0.1 (7.2) −1.5 (4.5) −4.0 (2.7) −3.0 (2.9) 0.02 (0.95) 
Birthweight (g) 






(573.6) 0.85 (0.73) 
Bold: p-value less than 0.05 for periodontal treatment (outside parenthesis) or milk fortifcation (inside parenthesis). BOP: Sites with 
bleeding on probing; CAL: clinical attachment loss; CRP: ultra-sensitive C-Reactive Protein; PD: pocket depth. 
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There was no signifcant difference in changes in calcium and vitamin D levels from 
T0 to T2 among intervention groups (Table 2). However, vitamin D levels tended to 
increase from T0 to T1 (pregnancy period) with the highest increase among the early PT 
plus Fortifcation group, but the results did not reach statistical signifcance at 0.05. Then, 
vitamin D levels fell after childbirth when the intervention ceased. No interactions between 
PT and fortifcation were detected on vitamin D and calcium levels. 
Regarding the metabolic markers, insulin levels decreased over time across the in-
tervention groups (Table 2). Although the late PT plus fortifcation group experienced 
the highest overall reduction (T2–T0) in insulin levels (−4.0 ± 2.7 µU/mL) compared to 
other groups, in the post hoc analysis with only the late PT group there was no signifcant 
difference between fortifcation and placebo. A detailed analysis (Table 3) revealed that 
there was a signifcant reduction in insulin levels from late pregnancy to postpartum (from 
T1 to T2) and this change was driven by the periodontal treatment, with those allocated in 
the late PT group experiencing the highest reduction in insulin levels. Therefore, the overall 
signifcant reduction in insulin levels among the late PT group was likely to be driven 
by changes from the 3rd trimester of pregnancy to 6–8 weeks postpartum. No signifcant 
differences in glucose levels were observed among the four intervention groups over time. 
Table 3. Detailed analysis of changes in outcomes over time according to intervention groups in 
pregnant and postpartum women participating in the IMPROVE trial. 
Early PT Late PT 
Fortifcation Placebo Fortifcation Placebo p 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Value 
Calcium (mg/dL) 
T1–T0 −0.36 (0.77) −0.46 (0.85) −0.38 (0.89) 0.06 (1.21) 0.37 (0.41) 
T2–T1 0.42 (0.49) −0.08 (0.64) 0.29 (0.71) −0.04 (1.3) 0.81 (0.10) 
ΔT 0.10 (1.0) −0.60 (0.7) −0.10 (0.6) 0.10 (0.5) 0.53 (0.75) 
Vitamin D (ng/mL) 
T1–T0 3.98 (7.82) −3.96 (15.6) 0.99 (7.53) 0.94 (8.3) 0.84 (0.17) 
T2–T1 −6.49 (8.65) 1.59 (7.28) −3.92 (7.71) −3.52 (5.81) 0.69 (0.11) 
ΔT −1.80 (9.5) −1.20 (12.1) −3.30 (6.7) −3.50 (5.4) 0.43 (0.97) 
CRP (mg/L) 
T1–T0 −3.5 (7) −3.2 (3.9) −0.01 (12.3) 1.2 (8.6) 0.09 (0.72) 
T2–T1 −1.9 (6.1) 1.3 (8.2) −5.6 (10.6) −5.9 (9.3) 0.04 (0.67) 
ΔT −5.9 (7.1) −1.3 (9.5) −4.0 (7.8) −4.2 (4.8) 0.90 (0.41) 
Glucose (mg/dL) 
T1–T0 2.94 (14.4) −3.40 (8.2) 0.22 (15) 3.20 (11.8) 0.67 (0.75) 
T2–T1 2.58 (21) 7.90 (11.4) 4.80 (14.2) 2.70 (10.5) 0.79 (0.83) 
ΔT 8.90 (16.9) 2.50 (8.7) 4.6 (12.9) 8.60 (11.8) 0.92 (0.99) 
Insulin (µU/mL) 
T1–T0 0.3 (3.7) 1.3 (4.8) 2.4 (3.5) 1.7 (4.8) 0.21 (0.98) 
T2–T1 −1.6 (6.5) −3.3 (4.3) −6.4 (3.6) −5.6 (4.6) <0.01 (0.93) 
ΔT 0.1 (7.2) −1.5 (4.5) −4.0 (2.7) −3.0 (2.9) 0.02 (0.95) 
Bold: p-value less than 0.05 for periodontal treatment (outside parenthesis) or milk fortification (inside parenthesis). 
Regarding the infammatory marker, CPR levels tended to reduce over time (delta: 
T2–T0) across the intervention groups; however, there was no signifcant difference between 
groups (Table 2). A detailed analysis Table 3) showed a more pronounced reduction in CRP 
during pregnancy (T1–T0, during pregnancy) in the early PT group compared to the late 
PT group but the p-value was borderline (0.09). On the other hand, there was a signifcant 
reduction in CRP levels from the 3rd trimester of pregnancy to the postpartum period in 
the late PT group compared to the early PT group. 
In the ITT analysis, the results presented similar patterns as in the per-protocol (Sup-
plementary Table S1). 
The correlation of the main effect of the interventions between the outcomes by the 
ANCOVA analysis showed that BOP worsens as serum levels of calcium increase. However, 
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this trend was not fully observed across all groups since the fortifcation and late PT group 
had the lesser pronounced trend, indicating some interaction effect between treatments 
(Sum Sq. = 2.07; p-value = 0.03) (Figure 2). 
Figure 2. Difference in the periodontal treatment and milk fortifcation effects of interventions 
(delta) in calcium and bleeding on probing. Late PT: Periodontal treatment postpartum. Early PT: 
Periodontal treatment during pregnancy. Fortifed: milk with the fortifcation of calcium and vitamin 
D. Placebo: milk without fortifcation. Delta of calcium (mg/dL) and bleeding on probing (%): 
levels in T2–levels in T0 (baseline). 
A delta equal to zero means no change between T0 and T2. Positive and negative 
results mean an increase and reduction in values from baseline, respectively. The results of 
ANCOVA test shows that the effect of bleeding on probing dental levels is signifcant at 
10% in the delta levels of calcium (Sum of Squares = 1.51; p-value = 0.076) and the effect 
of the milk fortifcation combined with periodontal treatment is signifcant at 5% in the 
delta levels of calcium (Sum Sq. = 2.07; p-value= 0.03), all adjusted for the effect of milk 
fortifcation (Sum Sq. = 0.37, p-value = 0.37) and periodontal treatment (Sum Sq. = 1.07, 
p-value = 0.13, Sum Sq. Residual = 21.6). 
Figure 3 shows that BOP was correlated with insulin levels indicating that if PT is 
not initiated during pregnancy the reduction expected in insulin levels overtime could 
have not been observed (Sum Sq. = 146.83; p-value ≤ 0.001). There was no difference 
between the fortifcation and the placebo group. Therefore, the analysis was not stratifed 
by fortifcation group. 
Nutrients 2021, 13, 783 10 of 15 
Figure 3. Difference in the effect of periodontal treatment intervention on delta insulin levels and 
delta bleeding on probing. Late PT: Periodontal treatment postpartum. Early PT: Periodontal treatment 
during pregnancy. Delta of insulin and bleeding on probing: levels in T2–levels in T0 (baseline). 
The results of ANCOVA test shows that the effect of periodontal treatment is signif-
cant at 5% in the delta levels of insulin (Sum of Squares = 210.03; p-value ≤ 0.001) and the 
impact of the periodontal treatment considering the delta levels of bleeding on probing 
is signifcative at 5% in the delta levels of insulin (Sum Sq. = 146.83; p-value ≤ 0.001), all 
adjusted for the effect of bleeding on probing alone (Sum Sq. = 8.49; p-value = 0.48; Sum Sq. 
Residual = 827.88). 
4. Discussion 
This exploratory analysis showed that periodontal treatment during pregnancy signif-
icantly decreased maternal BOP between baseline and postpartum even in a small sample 
of pregnant women. Periodontal disease is unpredictable and slowly progressive so that a 
clinically relevant difference in pocket depth and attachment loss would not be expected 
or detectable during the intervention period [31]. However, the absence of BOP is a pa-
tient observed health outcome and a reliable indicator of periods of periodontal disease 
stability and infammation status [31]. A previous qualitative study about the oral health 
of pregnant women in public healthcare centres in Brazil showed that gingival bleeding 
was perceived as the most frequent problem arising from pregnancy [32]. However, most 
women reported that they did not seek dental care or discussed this problem with their 
physicians during routine prenatal care. The bleeding was considered a common pregnancy 
issue by the majority of women [32]. 
Periodontal disease is a prevalent condition during pregnancy. Studies show that 
the prevalence can vary from 30 to 70% [33]. Pre-existing gingivitis and periodontitis 
conditions are aggravated during the reproductive period due to hormonal changes [3–5]. 
High levels of circulating progesterone associated with placental growth and accompanied 
by the increased levels of oestrogens can lead to gingival capillary dilatation, bleeding, and 
infammation [5]. 
While our results showed that PT during pregnancy improved BOP, there was a further 
tendency of a less pronounced increase in BOP among the late PT group receiving vitamin 
D/calcium-fortifed milk, suggesting a potential protective impact of the fortifcation; 
however, results were not statistically signifcant. Although this fnding is in line with 
previous literature, it is important to consider that our study was not powered to fnd a 
signifcant effect. A clinical trial with 85 Pakistani pregnant women (36 in the intervention 
group versus 49 in the placebo group) found that 4000 IU of vitamin D daily during 
6 months of pregnancy (2nd and 3rd trimesters) did not result in signifcant improvements 
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in BOP compared to the placebo group [34]. In that study, pregnant women did not receive 
PT [34]. Since vitamin D has immunomodulatory effects against bacterial infections it 
is expected that vitamin D in addition to PT might have a potential protective effect on 
periodontal clinical parameters. 
Elevated CRP levels during gestation is a marker of infammation [35]. As expected, 
there was an overall (T2–T0) reduction in CPR, which is a marker of infammation, in both 
the per-protocol and the ITT analyses. We also observed a more pronounced reduction in 
the early PT compared to late PT during pregnancy (T1–T0) while women were undergoing 
PT treatment. In fact, women in the late PT and placebo group experienced an average 
increase of 1.2 mg/L in CRP levels during pregnancy. Although the direction of these results 
suggests a potentially benefcial effect, the results did not reach statistical signifcance. 
Additionally, a signifcantly higher reduction in CRP levels from the 3rd trimester of 
pregnancy to postpartum in the late PT group compared to the early PT group was observed. 
This higher decrease in CRP in the late PT group might be explained by the fact that levels 
of CRP increase during pregnancy above non-pregnant levels and then gradually reduces 
after childbirth [36]. The cause of such an increase is still unknown [36]. Women in the 
early PT, on the other hand, already experienced a reduction in CRP levels from the second 
trimester to the third trimester and therefore had a less pronounced further reduction in 
CRP levels from the third trimester to postpartum compared to women in the late PT. 
The mean calcium levels tended to remain stable over time and there were no sig-
nifcant differences across groups despite the fortifcation. As all women consumed milk 
and therefore increased their overall calcium intake, this might explain why a signifcant 
difference in serum calcium levels between groups was not observed. The literature indi-
cates that total serum calcium normally falls throughout pregnancy, particularly during the 
peak of foetal demand that occurs in the third trimester [37]. Thus, although the results did 
not reach statistical signifcance, this fnding might indicate an overall protective effect of 
the intervention by adding milk to the diet on maternal calcium defciency and long-term 
bone health. This fnding highlights that a healthy and balanced maternal diet is critical to 
ensure that maternal nutritional needs, as well as the needs of the growing foetus, are met. 
In most low and middle-income countries, poor diets coupled with normal physiologic 
pregnancy changes can lead to micronutrient defciency [38]. It worth noting that there are 
maternal adaptations during pregnancy to meet the additional calcium demands [37]. The 
intestinal calcium absorption is doubled as early as 12 weeks and this may allow women 
to store calcium in advance to provide for the peak foetal demand in the third trimester 
via calcium mobilization from the maternal skeleton [37]. Concomitantly, the 24-h urine 
calcium increases by 12 weeks gestation, which can exceed the normal range, indicating an 
increase in maternal intestinal calcium absorption [39]. 
In this study, vitamin D levels tended to increase from T0 to T1 and then reduce in T2 
during the postpartum period. Contrary to expectation, we observed an overall (T2–T0) 
reduction in vitamin D levels in all groups. Although during the pregnancy period, vitamin 
D tended to be slightly higher in the fortifcation group compared to placebo in both early 
and late PT, results were not statistically signifcant. Also, we observed that vitamin D 
levels tended to reduce after childbirth when women were no longer consuming milk 
and undergoing periodontal treatment. However, previous studies have found that 25 
(OH)D decreases during chronic periodontal infammation while vitamin D concentration 
(25(OH)D) increases during acute periodontal infammation periods because of increased 
25-hydroxylase activity of periodontal cells [40]. We speculate that the same pattern might 
be observed in pregnant and postpartum. 
Insulin concentrations tend to increase during pregnancy and decrease during post-
partum [41]. Our results are consistent with the literature as we observed insulin reduction 
mainly in T2–T1, in all groups, and signifcantly in the fortifed milk and placebo groups 
that received PT during the postpartum. This fnding is compatible with hormonal changes 
that are expected in the postpartum period. Fasting insulin concentrations and insulin resis-
tance increase during pregnancy, especially in the 2nd and 3rd trimester [41], as observed 
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between T0 and T1 in this study. After delivery, insulin concentrations return to similar 
values to those of the pre-pregnancy period [41]. However, breastfeeding at least among 
obese women with gestational diabetes can infuence postpartum insulin concentration. A 
previous study observed signifcant reduction in insulin resistance in obese women with 
gestational diabetes with high-intensity breastfeeding in the early postpartum phase [42]. 
In the present study, we did not register whether pregnant women breastfed or not, and 
could not examine if this infuenced the results obtained in relation to the insulin concentra-
tions in the postpartum period and the difference observed between groups. It is important 
to note, that even though there were some differences in insulin concentrations between 
groups, in all groups the mean insulin concentration was within the normal range proposed 
by Murguía-Romero et al. [43]. None of the participants developed gestational diabetes. 
The fasting glucose concentrations tended to reduce during pregnancy (T0 to T1) 
and increase in the postpartum (T1 to T2) in all groups. These changes are consistent 
with previous literature [44]. Riskin-Mashiah et al. [44] observed a reduction of fasting 
glucose concentrations from the frst to the third trimester and an increase after delivery. 
Our results suggest that PT and milk fortifcation potentially infuenced glycaemic control 
during pregnancy and postpartum in women with periodontitis. However, it is important 
to highlight that all women consumed milk and a large prospective cohort study found 
that the intake of low-fat dairy was signifcantly and inversely associated with the risk 
of developing gestational diabetes [45]. The authors also reported that among pregnant 
women with a total dietary calcium intake below 1200 mg/day, a 200 mg per day increase in 
calcium intake was associated with a 22% reduction in the risk of gestational diabetes [45]. 
Our results also suggested that women allocated in the early PT plus fortifcation 
group gave birth to slightly heavier babies compared to the other groups. However, 
the results were not statistically signifcant. This fnding might also be explained by 
the fact that all women consumed milk as part of the intervention. Milk consumption 
regardless of micronutrient fortifcation is associated with foetal growth [46,47]. This 
association seems to be driven by milk protein, or milk components closely associated with 
protein, rather than by the fat or carbohydrate fractions of milk [46,47]. We did not collect 
specifc information on milk intake beyond what was supplied by the study. However, 
the study was conducted in a low-income area in Rio de Janeiro, Brazil and therefore milk 
consumption is expected to be low due to affordability issues. Therefore, a milk surplus 
was provided to prevent women from sharing their milk supply with their families and 
consequently ensure adequate consumption. In our previous study [24], we found an 
overall adherence to milk consumption (number of sachets consumed/ total number of 
sachets provided to participants) of 85.2%. 
This exploratory study was designed to assess the feasibility of a multicomponent 
intervention delivered in a resource-poor setting and metropolitan area of Rio de Janeiro, 
Brazil. Therefore, a large sample size was not required. Thus, the main limitation of this 
study is the small sample size. Although inferential statistics were performed the main 
aim was to uncover any relevant and potential associations among the study variables. 
Since we recruited a young population of women of childbearing age, it was antic-
ipated that chronic severe periodontitis which tends to progress with age would not be 
prevalent. Thus, we applied less rigid diagnostic criteria defned as the presence of one or 
more teeth with at least one of the periodontal sites with ≥4 mm of clinical attachment loss 
with the presence of bleeding on probing on the same site. The presence of bleeding on 
probing on the same site ensured the existence of local infammation. However, having 
applied stricter diagnostic criteria including ≥2 teeth with ≥4 mm of clinical attachment 
loss, only one pregnant woman would have been excluded from the study [25]. The ratio-
nale for recruiting women up to 20 weeks gestation was based on the previous literature 
suggesting that starting PT after the second trimester of gestation might be too late to 
reduce infammation [48]. The literature also suggests that the number of PT appointments 
(e.g., 1 treatment course during 1–2 appointments) in previous RCTs might not have been 
effective in preventing the progression of periodontal disease during pregnancy, indicating 
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that additional periodontal maintenance throughout gestation may be required [49]. Al-
though previous studies concluded [48–50] that a pre-pregnancy treatment might be the 
best preventive measure of negative gestational outcomes associated with periodontitis, 
many pregnancies are unplanned and such trials would be very diffcult to be conducted 
and would require a large sample size. 
In conclusion, this study, although a feasibility exploratory clinical trial, has provided 
invaluable data to the emerging feld of nutritional intervention for oral health as well 
as contributed to the literature on the importance of maternal oral health for systemic 
health and consequently gestational outcomes. A full-scale and defnitive trial is needed to 
establish clinical effectiveness. 
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